INOVIO PHARMACEUTICALS, INC.

Inovio Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved all four proposals, including the election of eight director nominees, the ratification of Ernst & Young LLP as the independent auditor, the advisory approval of executive compensation, and the amendment and restatement of the 2023 Omnibus Incentive Plan. Concurrently, the Board of Directors approved immediate amendments to the company's bylaws to enhance corporate governance, clarifying the Chairman's role and establishing a Lead Independent Director position.

INOVIO reported a Q1 2026 net loss of $(19.7) million, consistent with the prior year, and an improved net loss per share of $(0.28). The company's Biologics License Application for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP), is under active FDA review with a target PDUFA date of October 30, 2026, and commercial readiness plans are advancing. INOVIO also announced a clinical trial collaboration for INO-5412 in glioblastoma and strengthened its balance sheet with a $16.0 million equity offering in April 2026, extending its cash runway into Q1 2027.

Inovio Pharmaceuticals reported a net loss of $19.7 million for Q1 2026, with cash and equivalents decreasing to $26.3 million. The company disclosed substantial doubt about its ability to continue as a going concern beyond late Q4 2026, despite raising $16.0 million in an April 2026 offering. Additionally, the FDA accepted Inovio's BLA for INO-3107 for standard review but expressed preliminary concerns about its eligibility for the accelerated approval pathway, potentially requiring a costly Phase 3 trial.